Ortho/Stratagene MAb technology
Executive Summary
Two firms have rights to new E. coli-based monoclonal antibody technology developed at the Research Institute of the Scripps Clinic which potentially offers greater speed, variety and economy than the current mouse or human-based production media. Ortho parent J&J has the rights to license healthcare-related technologies developed by Scripps. The privately-held molecular biology products supplier Stratagene, has set up a new company, Stratacyte, to exploit and license the technology to the research community.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.